Curasight
Curasight to present at HC Andersen Capital and at HC Andersen Life Science seminar
The presentations will include an update on the business progress made by the company during the first half of 2023 and look ahead at the coming news flow expected in rest of 2023. Management will give an overall update on the company’s pipeline based on the proprietary uPAR theranostics platform and focused on diagnosing and treating brain and prostate cancer besides the newly signed global partnership agreement with Curium.
The HC Andersen Capital presentation of the company’s Interim Report Q2 2023 will be webcasted live 13:00 - 13:30 (CET), Wednesday 30 August 2023.
An archive of the presentation can be found on the HC Andersen Capital website as well as Curasight’s website, after the presentation is completed.
For more information – please click here
The HC Andersen Capital Life Science seminar will be webcasted live 11:30 - 11:55 (CET), Thursday 31 August 2023.
An archive of the presentation can be found on the HC Andersen Capital website as well as Curasight’s website, after the presentation is completed.
For more information – please click here
| Datum | 2023-08-25, kl 12:26 |
| Källa | Cision |
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!